PF-07284892 in Participants With Advanced Solid Tumors
Ontology highlight
ABSTRACT: The purpose of this first-in-patient, open label study is to determine the maximum tolerated dose and/or recommended dose for further study of PF-07284892 as a single agent and in combination with lorlatinib, encorafenib and cetuximab, or binimetinib and evaluate the pharmacokinetics, safety, and preliminary clinical activity of single agent and each combination therapy.
DISEASE(S): Solid Tumor,Non-small Cell Lung Cancer,Colorectal Cancer,Neoplasms
PROVIDER: 2370923 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA